Tatva Chintan Pharma Chem Limited has informed the Exchange that Board of Directors at its meeting held on May 16, 2026, recommended Final Dividend of Rs. 2 per equity share.
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Tatva Chintan Pharma Chem Limited reported strong audited financial results for FY 2025-26. Standalone revenue from operations grew to Rs. 4,963 million from Rs. 3,664 million in the previous year. Net profit surged dramatically to Rs. 390.82 million from just Rs. 1.10 million in FY 2025. The Board recommended a final dividend of Rs. 2 per equity share (20% on face value of Rs. 10) for shareholder approval at the ensuing AGM. The company also appointed M/s. Zarna Thakar & Associates as Cost Auditor and RSM Astute Consultech as Internal Auditor for FY 2026-27. The auditors issued unmodified opinions on both standalone and consolidated financial results.
The company delivered exceptional profit growth year-on-year, justifying the dividend payout. The Rs. 2 per share dividend provides a modest cash return to shareholders, though the actual yield will depend on the prevailing stock price. The positive earnings trajectory and clean audit opinion are constructive signals for investors.